護城河比較
最多三家已涵蓋的公司，逐項對照。每一項判斷都是人工編輯的判斷，而非公司揭露的數字——而且每一項都附有其引用依據。
| Snowflake | Pfizer | Super Micro Computer | |
|---|---|---|---|
| 護城河評級 | 窄 Narrow, not wide, because the FY2026 10-K documents a strong installed base and a competitive position the company itself says is under erosion. On the asset side: revenue of $4.7 billion (29% growth in each of the last three fiscal years), 13,328 total customers up from 10,996, 790 of the Forbes Global 2000 contributing about 43% of revenue, 733 customers above $1 million in trailing-12-month product revenue up from 576, a 125% net revenue retention rate, and more than 1,050 issued U.S. patents. Against that, Item 1A states plainly that adopting open data formats like Apache Iceberg means 'there is less customer “lock in” when our products are used in external environments' and that 'our support of open data formats may also reduce switching costs between us and our competitors'; that AWS, Azure and GCP 'generally compete in all of our markets' while also supplying the infrastructure a 'substantial majority of our business is run on'; and that the company remains loss-making at $1.3 billion of net loss for the year. | 正在侵蝕 The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. | 窄 The FY2026 10-K describes a genuine but bounded advantage. On the asset side the filing claims a modular Server Building Block Solutions architecture, over 3,500 R&D employees, in-house design control over many sub-systems, and that Supermicro believes it is 'the only major server, storage, and accelerated compute platform vendor that designs, develops, and manufactures a significant portion of its systems in the United States.' Against that, the same filing calls its market 'highly competitive, rapidly evolving,' concedes that 'most of our competitors have longer operating histories, significantly greater resources, greater name recognition, or deeper market penetration,' reports intensified competition from 'predominantly Asia-based' entrants 'leading to pricing pressure,' and states that pricing pressure has produced 'a continued decline of average selling prices across our business and we expect that these historical trends will continue.' It also disclaims patent dependence outright. A durable-but-shallow advantage in time-to-market and integration, sitting on top of a commoditizing box business, is narrow rather than wide. |
| 護城河類型 | 轉換成本 The filing makes its own affirmative claim of network effects — 'Our business benefits from powerful network effects. ... The more customers adopt our platform, the more data can be exchanged with other Snowflake customers, partners, data providers, and data consumers' — but the load-bearing, quantified evidence in the document points to switching costs. The platform is sold as the way to 'consolidate data into a single source of truth,' and the disclosed economics of that consolidation are a 125% net revenue retention rate and 733 customers above $1 million in trailing product revenue. Item 1A confirms the mechanism by naming what is at risk: open formats produce 'less customer “lock in”' and 'may also reduce switching costs.' The filing frames lock-in, not network density, as the thing erosion would take away. | 無形資產與智慧財產 The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. | 成本規模 The filing locates the advantage in design-and-manufacturing scale, not in IP or lock-in. It says the company manufactures the majority of its systems at its San Jose headquarters with assembly, test and QC also in Taiwan, the Netherlands and Malaysia, and that this structure lets it 'reduce time to delivery, mitigate the impact of tariffs and regional costs, and reduce overall manufacturing costs.' Its own list of principal competitive factors includes 'cost-effective design and manufacturing' and 'sufficient manufacturing capacity necessary to support market demand.' Intangibles are explicitly ruled out as the source: 'neither our business as a whole nor any of our principal businesses are materially dependent on a single patent,' with reliance placed 'primarily on trade secrets, technical know-how.' Switching costs are weak by the filing's own account: it 'typically sell[s] products pursuant to purchase orders rather than long-term purchase commitments,' and customers 'have, and others may in the future, cancel or defer purchase orders on short notice without incurring a significant penalty.' |
| 領先地位 | 並列領先者 The 10-K contains no ranking, market-share figure, or claim of leadership, and it names no non-hyperscaler competitor by name. The band rests on disclosed scale — $4.7 billion of revenue, 13,328 customers, 9,060 employees across 36 countries — set against the filing's own statement that 'many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical, and other resources than we do.' Co-leader among independent cloud data platforms; not a leader over AWS, Azure and GCP, which the filing says compete in all of its markets. | 並列領先者 The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' | 勢均力敵 The filing claims no market-share leadership and gives no share figure. It states 'we believe that we compete favorably with respect to most of these factors' while immediately conceding that 'most of our competitors have longer operating histories, significantly greater resources, greater name recognition, or deeper market penetration,' naming Cisco, Dell, Hewlett-Packard Enterprise and Lenovo plus ODMs Foxconn, Quanta Computer and Wiwynn. The one leadership claim it does make is narrow and structural — that it believes it is the only major vendor in its class manufacturing a significant portion of its systems in the United States — plus a stated goal (not an achievement) to 'be the first to market with superior product designs.' Competing favorably against larger, better-penetrated rivals without asserting share leadership is parity, not leadership. |
| 定價權 | 中等 The consumption model plus 125% net revenue retention shows real expansion pricing, and the filing argues it competes on 'pricing transparency and optimized price-performance.' But Item 1A limits how far that goes: competition 'may negatively impact our ability to acquire new customers ... put downward pressure on our prices and gross margins'; the company 'may not be able to ... offer as many discounts or free services as our competitors'; results depend on 'changes in our pricing model, including in response to significant price discounts by our competitors' and on 'customer optimization efforts that result in reduced consumption.' On the cost side, 'our costs and gross margins are significantly influenced by the prices we are able to negotiate with these public cloud providers, which in certain cases are also our competitors.' | 弱 Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. | 弱 The filing states pricing pressure explicitly and repeatedly. 'Historically, these pricing pressures have led to a continued decline of average selling prices across our business and we expect that these historical trends will continue.' On large orders: 'Large orders are generally subject to intense competition and pricing pressure which can have an adverse impact on our margins and results of operations.' It concedes it has 'accepted customer orders with various types of component pricing protection' which 'increased our exposure to component pricing fluctuations and have adversely affected our financial results in certain quarters,' and that FY2026 industry supply constraints in memory, storage, GPUs and CPUs affected 'the pricing of these items.' Its stated remedy is aspirational rather than realized: it 'must continue to develop more advanced, differentiated products that command a premium.' The filing gives no gross-margin trend in Item 1/1A; margin appears there only as a downside — excess or obsolete inventory 'would reduce our gross margin.' |
| 綜述 | Snowflake's advantage in its FY2026 10-K rests on being the consolidation point for enterprise data: a multi-cluster shared-data architecture with proprietary columnar storage and automatic micro-partitioning, delivered across three major public clouds and 53 interconnected regional deployments, that customers adopt as a single governed source of truth and then expand on — 125% net revenue retention, 790 of the Forbes Global 2000 as customers. The filing layers a collaboration claim on top, with sharing 'generally without copying or moving the underlying data' and a Marketplace of 'hundreds of live, ready-to-query third-party data sets and data products.' The same document is unusually candid about the counter-pressure: Iceberg and open formats reduce lock-in by the company's own account, the three hyperscalers compete across every market while setting the cloud costs that 'significantly influence' gross margins, and frontier AI model providers 'may seek to vertically integrate ... by expanding into the data storage and management layers.' | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. | Supermicro's edge, as its FY2026 10-K frames it, is speed and integration built on a common modular parts bin: it works with NVIDIA, Intel and AMD to 'align the design of our new products with their product release schedules,' then 'quickly assemble a broad portfolio of solutions by leveraging common building blocks across product lines.' During FY2026 it pushed that advantage up a level, growing Data Center Building Block Solutions to 'more than ten key subsystems' — coolant distribution units, heat exchangers, power shelves, switching, management software — and deploying DLC-2 liquid cooling the filing credits with up to 98% per-rack heat capture and up to 40% lower data center power draw. But the filing's competition and risk discussion is candid that this sits inside a price-taking market: ASPs decline structurally, one customer exceeded 10% of net sales in FY2026, and ODMs 'benefit from their scale and very low-cost manufacturing' while increasingly selling their own brands. |
| 產業鏈位置 | Sits at the enterprise data and governance layer of the AI stack, and the AI exposure is explicit rather than incidental: the filing brands the product the 'AI Data Cloud,' lists AI as a product category, and put Snowflake Intelligence, Cortex Agents and a Managed MCP Server into general availability during the fiscal year. It is a buyer of hyperscaler compute and of third-party frontier models — 'strategic partnerships with foundational model providers deliver state-of-the-art models natively within Snowflake Cortex AI,' with stated 'model neutrality' — and a supplier of governed enterprise data and GPU-backed managed compute to AI applications built on top. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. | Downstream system integrator: it converts third-party accelerators and CPUs (NVIDIA Blackwell/GB300 NVL72, AMD Instinct MI350, Intel Xeon 6) into validated racks, liquid cooling and full data-center building blocks sold to cloud service providers and enterprises. The AI angle is central, not incidental — the filing devotes a risk factor titled 'The AI industry has driven a significant portion of our recent success' and states 'A portion of the recent success of our server and storage solutions has been dependent on the integration of our products and services within the AI industry.' |
| 產品（市佔 / 門檻） |
|
|
|
| 長週期投票 | +0.13 權重 0.20 · 群體判斷 neutral 編輯先驗，未經回測。 | -0.17 權重 0.20 · 群體判斷 bearish 編輯先驗，未經回測。 | -0.01 權重 0.20 · 群體判斷 neutral 編輯先驗，未經回測。 |